Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Nox2 in regulatory T cells promotes angiotensin II–induced cardiovascular remodeling
Amber Emmerson, … , Giovanna Lombardi, Ajay M. Shah
Amber Emmerson, … , Giovanna Lombardi, Ajay M. Shah
Published April 24, 2018
Citation Information: J Clin Invest. 2018;128(7):3088-3101. https://doi.org/10.1172/JCI97490.
View: Text | PDF
Research Article Cardiology Immunology

Nox2 in regulatory T cells promotes angiotensin II–induced cardiovascular remodeling

  • Text
  • PDF
Abstract

The superoxide-generating enzyme Nox2 contributes to hypertension and cardiovascular remodeling triggered by activation of the renin-angiotensin system. Multiple Nox2-expressing cells are implicated in angiotensin II–induced (Ang II–induced) pathophysiology, but the importance of Nox2 in leukocyte subsets is poorly understood. Here, we investigated the role of Nox2 in T cells, particularly Tregs. Mice globally deficient in Nox2 displayed increased numbers of Tregs in the heart at baseline, whereas Ang II–induced effector T cell (Teff) infiltration was inhibited. To investigate the role of Treg Nox2, we generated a mouse line with CD4-targeted Nox2 deficiency (Nox2fl/flCD4Cre+). These animals showed inhibition of Ang II–induced hypertension and cardiac remodeling related to increased tissue-resident Tregs and reduction in infiltrating Teffs, including Th17 cells. The protection in Nox2fl/flCD4Cre+ mice was reversed by anti-CD25 antibody depletion of Tregs. Mechanistically, Nox2–/y Tregs showed higher in vitro suppression of Teff proliferation than WT Tregs, increased nuclear levels of FoxP3 and NF-κB, and enhanced transcription of CD25, CD39, and CD73. Adoptive transfer of Tregs confirmed that Nox2-deficient cells had greater inhibitory effects on Ang II–induced heart remodeling than WT cells. These results identify a previously unrecognized role of Nox2 in modulating suppression of Tregs, which acts to enhance hypertension and cardiac remodeling.

Authors

Amber Emmerson, Silvia Cellone Trevelin, Heloise Mongue-Din, Pablo D. Becker, Carla Ortiz, Lesley A. Smyth, Qi Peng, Raul Elgueta, Greta Sawyer, Aleksandar Ivetic, Robert I. Lechler, Giovanna Lombardi, Ajay M. Shah

×

Figure 4

Nox2fl/flCD4Cre+ mice are resistant to development of hypertension and heart remodeling induced by Ang II treatment.

Options: View larger image (or click on image) Download as PowerPoint
Nox2fl/flCD4Cre+ mice are resistant to development of hypertension and h...
Nox2fl/flCD4Cre+ and Nox2fl/fl littermate controls were treated with Ang II (1.1 mg/kg/d) or saline (Sham) infusion. (A–C) Number of CD45+TCRβ+CD4+ and CD45+TCRβ+CD8+ T cells in heart digests by flow cytometry after 3 days of Ang II treatment. (D) Relative numbers of Tregs in heart digests after 3 days of Ang II treatment. Representative plots are shown to the left and mean data to the right. (E–G) Changes in systolic BP, interstitial cardiac fibrosis, and cardiomyocyte cross-sectional area (CSA) 14 days after Ang II infusion. *P < 0.05 compared with Nox2fl/fl control group by 1-way ANOVA followed by Tukey’s post-test (B, C, F, and G), 2-way ANOVA (E), or unpaired t test (D); n = 5–11 per group.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts